Supernus Pharmaceuticals | SUPN - Equity Capital And Reserves


Supernus Pharmaceuticals reported $1.06B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.13B 1.3B Dec/2025
ANI Pharmaceuticals USD 540.72M 34.91M Dec/2025
Aurora Cannabis CAD 536.36M 30.74M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 758.17M 22.16M Dec/2025
Cara Therapeutics USD 27.87M 5.06M Sep/2025
Corcept Therapeutics USD 647.8M 15.9M Dec/2025
Eisai JPY 889.64B 35.21B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Novo Nordisk DKK 194.05B 24.15B Dec/2025
Pacira USD 693.11M 34.1M Dec/2025
Perrigo USD 2.94B 1.51B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Xeris Pharmaceuticals USD 13.69M 14.55M Dec/2025